Dolby Laboratories (DLB) reset its leadership with the appointment of Marc Whitten as Chief Executive Officer and President on August 27, 2026, following Kevin Yeaman’s retirement and transition into a consulting role.
Recent trading shows momentum building in the near term for Dolby Laboratories, with a 90 day share price return of 17.83% and a 7 day move of 1.45% at a last close of US$62.32. However, the 1 year total shareholder return is still down 11.8% and the 5 year total shareholder return is down 29.21%, which suggests that excitement around the CEO transition is emerging against a longer track record of weaker investor outcomes.
Scan how leadership stories like Dolby Laboratories translate into price action by reviewing a curated set of 17 high quality undiscovered gems with similarly strong fundamentals and under-the-radar profiles.
Bulls argue Dolby Laboratories is finally being priced closer to its audio and video franchise strength, while bears see a short term leadership sugar high. Which story fits the current valuation setup better?
On the most followed narrative, Dolby Laboratories screens as undervalued with a fair value of $78.33 against a last close of $62.32. This puts the CEO reset in the context of a stock still priced below that narrative estimate.
Strong adoption and broader support of Dolby technologies by top device makers (Samsung, Xiaomi, LG, Motorola, OPPO) and social media platforms in China indicate a structural increase in addressable markets and embedded royalty potential as global proliferation of connected devices and immersive content consumption continues, driving sustained licensing revenue growth.
Read the complete narrative. Read the complete narrative.
Want to understand why this valuation work sees Dolby Laboratories growing into a larger earnings base with higher profitability and a richer multiple attached to those future profits? The key is how licensing, margins, and monetisation mix together in the forecast.
Result: Fair Value of $78.33 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the Dolby Laboratories story can break if device makers lean harder into royalty free codecs, or if weakness in core consumer electronics drags on licensing volumes.
Find out about the key risks to this Dolby Laboratories narrative.
Mixed feelings about Dolby Laboratories so far. With both concern and optimism in play, it may be helpful to move quickly and weigh both sides by reviewing the 4 key rewards and 1 important warning sign.
Do not stop with Dolby Laboratories. The quickest way to stress test your thinking is to line it up against fresh opportunities pulled from different corners of the market.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com